Proliferative Retinal Detachment

Back

Background

Proliferative vitreoretinopathy (PVR) is the most common cause of failure in retinal detachment surgery.[1, 2, 3, 4, 5, 6, 7, 8, 9] It can occur in untreated eyes or occur after pneumatic retinopexy, cryotherapy, laser retinopexy, scleral buckling, or vitrectomy.[4, 7, 8] Because excessive retinopexy and operating on inflamed eyes can cause proliferative vitreoretinopathy, some cases should be considered iatrogenic. Epimacular membranes occurring after retinal detachment surgery can be thought of as limited proliferative vitreoretinopathy. Proliferative vitreoretinopathy can occur from glial or retinal pigment epithelium (RPE) proliferation.[1, 2, 3, 10, 11, 12, 13] PVR can also occur in diabetic traction retinal detachment cases if there are associated retinal breaks. Penetrating or blunt trauma may also result in proliferative vitreoretinopathy.

Also see the clinical guideline summary from the American Academy of Ophthalmology, Posterior vitreous detachment, retinal breaks, and lattice degeneration.

Pathophysiology

Proliferative vitreoretinopathy is a reparative process, similar to a keloid, initiated by full- or partial-thickness retinal breaks, retinopexy, and other types of retinal damage. Loss of contact inhibition causes the surrounding glial or RPE cells to migrate to one or both surfaces of the retina.[1] Although the cells exhibit modest mitotic activity, it is largely a hypocellular process. Glial or RPE cells migrate further and cover the posterior surface of the detached posterior hyaloid face.[9, 10, 13, 14] Fibronectin-lined coated pits serve as attachments of RPE or glial cells to collagen fibers and other components of the extracellular matrix. The migration/contraction mechanism causes tangential force on the retina via multiple star folds and fixed folds.[13, 15, 14] The collagen fibers of anterior and posterior vitreous cortex contract because of a similar hypocellular contraction process.

Epidemiology

Frequency

United States

Of all retinal detachment surgery cases, 5-10% develop proliferative vitreoretinopathy.[8]

International

Worldwide incidence is the same as that in the United States.

Mortality/Morbidity

Proliferative vitreoretinopathy has no associated mortality. Morbidity is limited to blindness in the affected eye if not treated successfully. If several operations are required to repair proliferative vitreoretinopathy, poor vision may result even with a successfully attached retina.

Race

No known racial predilection exists for proliferative retinal detachment.

Sex

No known sexual predilection exists for proliferative retinal detachment.

Age

Although proliferative vitreoretinopathy can occur at all ages, some observers believe that proliferative tissue may develop more rapidly in children.

History

History findings include the following:

Physical

Retinal examination using binocular indirect ophthalmoscopy reveals the following:

Causes

Retinal breaks directly or indirectly cause most cases of proliferative vitreoretinopathy. Direct causation is a result of the loss of contact inhibition of retinal glial cells and RPE cells. Proliferative vitreoretinopathy may also result from cryopexy, diathermy, and laser retinopexy, especially if excessive. Repeated retinal surgery increases the risk for development or worsening of proliferative vitreoretinopathy.

Gas and silicone may contribute to proliferative vitreoretinopathy by sequestrating RPE, inflammatory, and glial cells; fibronectin; various cytokines; and fibrin at the retinal surface.

Imaging Studies

Diagnostic ultrasonography is only necessary if opacities of the cornea, the anterior chamber, or the lens; pupillary membranes; retro–intraocular lens (IOL) membranes; or vitreous opacities prevent optical visualization of the retina.

Procedures

Binocular indirect ophthalmoscopy is performed for diagnostic purposes. Contact lens examination can be used with slit lamp biomicroscopy for higher magnification and better resolution.

B-scan diagnostic ultrasonography is performed if the retina cannot be seen because of corneal disease, cataract, posterior capsular opacification, vitreitis, or vitreous hemorrhage.

Histologic Findings

Biopsy is never indicated, and histologic samples should not be obtained during surgery. Minimal mitotic activity with significant interaction between retinal pigment epithelium (RPE) and glial cells and extracellular matrix has been reported in pathologic specimens.[13, 17, 18]

Medical Care

Topical and subconjunctival or retrobulbar repository steroids should be used at the time of surgery for all patients who are not steroid glaucoma responders. Using topical and subconjunctival steroids may avoid the adverse effects associated with oral corticosteroids.

Intraocular steroids, 5-fluorouracil (5-FU), daunomycin, and low-dose radiation are not effective in this disorder.[19, 20, 21, 22]

Surgical Care

The surgical objective is to enable retinal conformation to the retinal pigment epithelium (RPE). In cases of moderate star folds without static vitreous traction, scleral buckling without vitreous surgery is indicated. Minimal retinopexy to the breaks should be used to avoid both inflammation and further proliferation. To reduce the incidence of recurrent proliferative vitreoretinopathy (PVR) and inflammation, retreatment of the RPE and excessive retinopexy should be avoided. Post-reattachment retinopexy made possible by fluid-air exchange or liquid perfluorocarbon-assisted drainage of subretinal fluid helps reduce proliferation and overtreatment of the RPE, but it is applicable only to vitrectomy. Laser probably causes less proliferative vitreoretinopathy than cryotherapy, but it is impractical during scleral buckling surgery.[4, 5, 6, 7]

A broad, moderately high, encircling buckle with a smooth contour is an option for mild proliferative vitreoretinopathy, although the author of this article and an increasing number of surgeons use a vitrectomy- approach, preferably with a combined scleral buckle. If a buckle approach is chosen, the following is a simplified, effective approach to scleral buckling:

Perform vitreous surgery[14, 23, 24] when it is anticipated that scleral buckling cannot sufficiently compensate for vitreous traction and periretinal membrane contraction to reattach the retina.[8, 24, 25, 26] Scleral buckling is not minimally invasive or sutureless and induces on average of 2.74 D of myopia, which is unacceptable to patients who have undergone Lasik or refractive cataract surgery. In addition, scleral buckling is associated with a significant incidence of strabismus, extruded/infected buckles, and conjunctival/Tenon capsule damage, which negatively affects subsequent glaucoma filtration surgery. Combining a scleral buckle with vitrectomy (ie, vit-buckle) is unnecessary for the same reasons and does not improve outcomes but is still in common use. Note the following:

Internal drainage of the SRF should precede fluid-air exchange to enable removal of all posterior SRF through preexisting peripheral retinal breaks.[14, 23, 24] Note the following:

Retinectomy is as follows:

Gas or silicone oil surface tension management is required in all cases requiring vitrectomy.[14, 23, 24] Note the following:

Surface tension management with highly purified silicone oil (1000 centistokes)[27, 28, 29, 30, 31, 32] is preferable to gas for most advanced or recurrent proliferative vitreoretinopathy cases. Note the following:

Consultations

General ophthalmologists should refer proliferative vitreoretinopathy cases to a vitreoretinal surgeon.

Activity

The ultimate strength of retinopexy lesions is reached 7-10 days after application.

Gas and silicone bubbles float in aqueous humor; therefore, head positioning is crucial to developing adherence in the 10-day period after surgery.

C3 F8 has been shown to be more effective than SF6 in management of proliferative vitreoretinopathy. Apparently, it is because the bubble duration is typically 3 weeks with C3 F8, while it is only 1 week with SF6.

Bed rest is not required as long as proper head positioning can be achieved in the postoperative period.

Patients with inferior retinal breaks must be prone for 7-10 days after surgery using either silicone or gas.

Medication Summary

Subconjunctival dexamethasone is indicated at the end of surgery, unless the patient is a steroid glaucoma responder. Topical difluprednate and prednisolone acetate are the topical drugs of choice and should be used at 3-4 times per day.

Betamethasone (Diprolene, Betatrex)

Clinical Context:  For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.

Prednisolone acetate (Pred Forte)

Clinical Context:  Used to suppress inflammation. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reducing capillary permeability.

Triamcinolone (Kenalog)

Clinical Context:  Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. Longer duration creates additional steroid glaucoma risk in patients who are steroid responders.

Class Summary

Have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.

Further Outpatient Care

All patients must be examined on the first postoperative day to determine if increased IOP, flat chamber, incorrect patient positioning, or endophthalmitis (a rare finding) is present. Most patients are then examined in 1-3 weeks.

Further Inpatient Care

Outpatient surgery for vitreoretinal surgery is the criterion standard. Concomitant medical conditions should determine the need for an inpatient approach.

Inpatient & Outpatient Medications

Topical fourth-generation fluoroquinolones (Vigamox) are used 4 times/day for approximately 1 week after surgery. All patients receive subconjunctival cefazolin (vancomycin if allergic to penicillins) and subconjunctival ceftriaxone at the end of surgery. Systemic antibiotics are not indicated.

Topical cycloplegics, such as Cyclogyl 1%, are used 2-3 times/day for 2-3 weeks after surgery.

Subconjunctival steroids, such as Kenalog (triamcinolone acetonide), are used in all patients except those who are steroid responders. The author never uses systemic steroids in these patients.

Topical steroids are used in all patients who are not steroid responders. The drops are administered 4 times/day. Prednisolone acetate 1% is the preferred agent.

Transfer

General ophthalmologists should transfer patients with proliferative vitreoretinopathy (PVR) to vitreoretinal surgeons.

Deterrence/Prevention

Excessive retinopexy (especially cryopexy), operating on inflamed eyes, bleeding, iris trauma, excessive operating times, retained lens material, viscoelastics, and excessive operative trauma contribute to recurrent proliferative vitreoretinopathy.

Complications

Recurrent proliferative vitreoretinopathy is the most common complication, occurring at a frequency of 25-50%.[8, 14, 23, 24]

Cataracts may occur from prolonged gas or silicone oil contact with the lens.

Uveitis may occur from excessive retinopexy, lengthy surgery, iris trauma, or retained lens material.

Intravitreal, anterior chamber, subretinal, or suprachoroidal hemorrhage may occur.

Glaucoma secondary to uveitis, excessive gas bubbles, pupillary block, silicone oil emulsification and surgical trauma to vortex veins or aqueous veins may occur. Steroid-associated glaucoma due to injected or topical steroids may also occur.

Ocular or periocular manifestations are as follows:

Prognosis

The anatomical success rate is dependent on the patient mix, the technique used, unknown patient factors, and the surgeon's skill. The success rate of anatomical reattachment ranges from 50%-90%.[14, 23, 24] The success rate decreases with an increasing number of surgical procedures performed on the eye.

The visual prognosis is dependent on location, duration and height of the detachment, media clarity, epimacular membranes, and other unknown factors.

Patient Education

Inform the patients about positioning, activity, visual prognosis, complications, medications, anesthesia risk factors, and anatomical and visual success rates.

Author

Steve Charles, MD, Founder and CEO of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine

Disclosure: Received royalty and consulting fees for: Alcon Laboratories.

Specialty Editors

Simon K Law, MD, PharmD, Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Andrew A Dahl, MD, FACS, Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Disclosure: Nothing to disclose.

Additional Contributors

Russell P Jayne, MD, Vitreoretinal Surgeon, The Retina Center at Las Vegas

Disclosure: Nothing to disclose.

References

  1. Sethi CS, Lewis GP, Fisher SK, et al. Glial remodeling and neural plasticity in human retinal detachment with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2005 Jan. 46(1):329-42. [View Abstract]
  2. Coral K, Angayarkanni N, Gomathy N, Bharathselvi M, Pukhraj R, Rupak R. Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthalmol Vis Sci. 2009 Aug. 50(8):3607-12. [View Abstract]
  3. Praidou A, Klangas I, Papakonstantinou E, et al. Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res. 2009 Feb. 34(2):152-61. [View Abstract]
  4. Rodriguez de la Rua E, Pastor JC, Aragon J, et al. Interaction between surgical procedure for repairing retinal detachment and clinical risk factors for proliferative vitreoretinopathy. Curr Eye Res. 2005 Feb. 30(2):147-53. [View Abstract]
  5. Tsui I, Schubert HD. Retinotomy and silicone oil for detachments complicated by anterior inferior proliferative vitreoretinopathy. Br J Ophthalmol. 2009 Sep. 93(9):1228-33. [View Abstract]
  6. Li W, Zheng J, Zheng Q, Wu R, Wang X, Xu M. Clinical complications of Densiron 68 intraocular tamponade for complicated retinal detachment. Eye (Lond). 2010 Jan. 24(1):21-8. [View Abstract]
  7. Tinley CG, Gray RH. Routine, single session, indirect laser for proliferative diabetic retinopathy. Eye (Lond). 2009 Sep. 23(9):1819-23. [View Abstract]
  8. Abrams GW, Azen SP, McCuen BW 2nd, Flynn HW Jr, Lai MY, Ryan SJ. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11. Arch Ophthalmol. 1997 Mar. 115(3):335-44. [View Abstract]
  9. Anderson DH, Stern WH, Fisher SK, Erickson PA, Borgula GA. The onset of pigment epithelial proliferation after retinal detachment. Invest Ophthalmol Vis Sci. 1981 Jul. 21(1 Pt 1):10-6. [View Abstract]
  10. Campochiaro PA. Pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol. 1997 Feb. 115(2):237-41. [View Abstract]
  11. Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol. 1985 Apr. 103(4):576-9. [View Abstract]
  12. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol. 1984 Dec. 102(12):1830-3. [View Abstract]
  13. Campochiaro PA, Jerdan JA, Glaser BM, Cardin A, Michels RG. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol. 1985 Sep. 103(9):1403-5. [View Abstract]
  14. Charles S. Methodology and research on proliferative vitreoretinopathy. Presented at: Retina Society Meeting: Cleveland, OH; Nov 1985.
  15. Chandler DB, Rozakis G, de Juan E Jr, Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol. 1985 Jun 15. 99(6):686-90. [View Abstract]
  16. Ando F, Kondo J. A plastic tack for the treatment of retinal detachment with giant tear. Am J Ophthalmol. 1983 Feb. 95(2):260-1. [View Abstract]
  17. Laqua H, Machemer R. Clinical-pathological correlation in massive periretinal proliferation. Am J Ophthalmol. 1975 Nov. 80(5):913-29. [View Abstract]
  18. Mandelcorn MS, Machemer R, Fineberg E, Hersch SB. Proliferation and metaplasia of intravitreal retinal pigment epithelium cell autotransplants. Am J Ophthalmol. 1975 Aug. 80(2):227-37. [View Abstract]
  19. Patel NN, Bunce C, Asaria RH, Charteris DG. Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina. 2004 Dec. 24(6):883-7. [View Abstract]
  20. Santana M, Wiedemann P, Kirmani M, et al. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit. Graefes Arch Clin Exp Ophthalmol. 1984. 221(5):210-3. [View Abstract]
  21. Stern WH, Lewis GP, Erickson PA, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol. 1983 Jul. 96(1):33-42. [View Abstract]
  22. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980 Dec. 90(6):810-6. [View Abstract]
  23. Charles S. Vitrectomy for retinal detachment. Trans Ophthalmol Soc U K. 1980. 100(4):542-9. [View Abstract]
  24. Charles S. Vitreous surgery for proliferative vitreoretinopathy. Presented at: Vitreous Society Meeting: Orlando, FL; Oct 1985.
  25. Cibis PA. Vitreous transfer and silicone injections. Trans Am Acad Ophthalmol. 1964. 68:983.
  26. Cibis PA, Becker B, Okun E, et al. The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol. 1962. 68:590.
  27. Meredith TA, Lindsey DT, Edelhauser HF, Goldman AI. Electroretinographic studies following vitrectomy and intraocular silicone oil injection. Br J Ophthalmol. 1985 Apr. 69(4):254-60. [View Abstract]
  28. Momirov D, van Lith GH, Zivojnovic R. Electroretinogram and electrooculogram of eyes with intravitreously injected silicone oil. Ophthalmologica. 1983. 186(4):183-8. [View Abstract]
  29. Ober RR, Blanks JC, Ogden TE, Pickford M, Minckler DS, Ryan SJ. Experimental retinal tolerance to liquid silicone. Retina. 1983. 3(2):77-85. [View Abstract]
  30. Ober RR, Ryan SJ, Minckler DS, et al. Ocular tolerance to liquid silicone. Invest Ophthalmol Vis Sci. 1988. 19 Suppl:47.
  31. Okun E. Intravitreal surgery utilizing liquid silicone. A long term followup. Trans Pac Coast Otoophthalmol Soc Annu Meet. 1968. 49:141-59. [View Abstract]
  32. Okun E, Arribas N, Johnston GP. Therapy of retinal detachment complicated by massive preretinal fibroplasia. Long-term follow-up of patients treated with intravitreal liquid silicone. Bibl Ophthalmol. 1969. 79:563-71. [View Abstract]
  33. Ando F. Intraocular hypertension resulting from pupillary block by silicone oil. Am J Ophthalmol. 1985 Jan 15. 99(1):87-8. [View Abstract]
  34. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. 1982 Oct. 94(4):458-67. [View Abstract]
  35. de Juan E Jr, Hickingbotham D, Machemer R. Retinal tacks. Am J Ophthalmol. 1985 Mar 15. 99(3):272-4. [View Abstract]
  36. Diddie KR, Azen SP, Freeman HM, et al. Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. Ophthalmology. 1996 Jul. 103(7):1092-9. [View Abstract]
  37. Dieudonne SC, La Heij EC, Diederen R, et al. High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2004 Nov. 45(11):4113-8. [View Abstract]
  38. Foerster MH, Esser J, Laqua H. Silicone oil and its influence on electrophysiologic findings. Am J Ophthalmol. 1985 Feb 15. 99(2):201-6. [View Abstract]
  39. Freeman KD, Gregor ZJ. Electrophysiological responses after vitrectomy and intraocular tamponade. Trans Ophthalmol Soc UK. 1985. 104:129.
  40. Glaser BM. A new method of treating giant tears without patient rotation with the use of intraocular gas and silicone oil. Presented at: Annual Meeting of American Academy of Ophthalmology: Atlanta, GA; Oct 2 1985.
  41. Glaser BM, Vidaurri-Leal J, Michels RG, Campochiaro PA. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. 1993 Apr. 100(4):466-70. [View Abstract]
  42. Han DP, Lewis MT, Kuhn EM, et al. Relaxing retinotomies and retinectomies. Surgical results and predictors of visual outcome. Arch Ophthalmol. 1990 May. 108(5):694-7. [View Abstract]
  43. Kohno T, Sorgente N, Patterson R, Ryan SJ. Fibronectin and laminin distribution in bovine eye. Jpn J Ophthalmol. 1983. 27(3):496-505. [View Abstract]
  44. Kohno T, Sorgente N, Ryan SJ. Fibronectin distribution at the vitreoretinal interface. Invest Ophthamol Vis Sci. 1983. 24:240.
  45. Labelle P, Okun E. Ocular tolerance to liquid silicone. An experimental study. Can J Ophthalmol. 1972 Apr. 7(2):199-204. [View Abstract]
  46. Laqua H, Machemer R. Glial cell proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975 Oct. 80(4):602-18. [View Abstract]
  47. Lewis H, Aaberg TM. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol. 1991 Jan 15. 111(1):15-9. [View Abstract]
  48. Machemer R. Massive periretinal proliferation (MPP) I. Pigment epithelium proliferation. Mod Probl Ophthalmol. 1975. 15:227. [View Abstract]
  49. Machemer R. Massive periretinal proliferation: a logical approach to therapy. Trans Am Ophthalmol Soc. 1977. 75:556-86. [View Abstract]
  50. Machemer R. Pathogenesis and classification of massive periretinal proliferation. Br J Ophthalmol. 1978 Nov. 62(11):737-47. [View Abstract]
  51. Machemer R. Role of the pigment epithelium in vitreous pathology. Trans Ophthalmol Soc U K. 1975. 95(3):402. [View Abstract]
  52. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991 Aug 15. 112(2):159-65. [View Abstract]
  53. Machemer R, Laqua H. A logical approach to the treatment of massive periretinal proliferation. Ophthalmology. 1978 Jun. 85(6):584-93. [View Abstract]
  54. Machemer R, Laqua H. Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975 Jul. 80(1):1-23. [View Abstract]
  55. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979. 77:171-80. [View Abstract]
  56. Machemer R, van Horn D, Aaberg TM. Pigment epithelial proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol. 1978 Feb. 85(2):181-91. [View Abstract]
  57. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998 Jul-Aug. 43(1):3-18. [View Abstract]
  58. Scott JD. A rationale for the use of liquid silicone. Trans Ophthalmol Soc U K. 1977 Jul. 97(2):235-7. [View Abstract]
  59. Scott JD. The treatment of massive vitreous retraction by the separation of preretinal membranes using liquid silicone. Mod Probl Ophthalmol. 1975. 15:285.
  60. Silicone Study Report 2. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Arch Ophthalmol. 1992 Jun. 110(6):780-92. [View Abstract]
  61. Sternberg P Jr, Machemer R. Results of conventional vitreous surgery for proliferative vitreoretinopathy. Am J Ophthalmol. 1985 Jul 15. 100(1):141-6. [View Abstract]
  62. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004 Jun. 137(6):1105-15. [View Abstract]
  63. Van Horn DL, Aaberg TM, Machemer R, Fenzl R. Glial cell proliferation in human retinal detachment with massive periretinal proliferation. Am J Ophthalmol. 1977 Sep. 84(3):383-93. [View Abstract]
  64. Wiedemann P, Sorgente N, Bekhor C, Patterson R, Tran T, Ryan SJ. Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci. 1985 May. 26(5):719-25. [View Abstract]
  65. Wiedemann P, Sorgente N, Kirmani M. Daunorubicin of experimental MPP-effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci. 1983. 24 (Suppl):241.